Insulin stimulates interleukin-6 and tumor necrosis factor-α gene expression in human subcutaneous adipose tissue

American Journal of Physiology - Endocrinology and Metabolism

Volumn 286, Issue 2 49-2, 2004, Pages

  Krogh Madsen, Rikke ^a   Plomgaard, Peter ^a   Keller, Pernille ^a   Keller, Charlotte ^a   Pedersen, Bente Klarlund ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Cytokines; Euglycemic clamp

Indexed keywords

INSULIN; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADULT; ARTICLE; CELL CULTURE; CLAMP; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HORMONE ACTION; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE; MUSCLE BIOPSY; NORMAL HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SKELETAL MUSCLE;

EID: 0942276518     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00274.2003     Document Type: Article

References (32)

1. Berghe, G van den, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, and Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359-1367, 2001.
2. Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jorgensen T, and Pedersen BK. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol 132: 24-31, 2003.
3. Carey AL, Lamont B, Andrikopoulos S, Koukoulas I, Proietto J, and Febbraio MA. Interleukin-6 gene expression is increased in insulin-resistant rat skeletal muscle following insulin stimulation. Biochem Biophys Res Commun 302: 837-840, 2003.
4. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60: 349-356, 2001.
5. Ershler WB and Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51: 245-270, 2000.
6. Fasshauer M, Klein J, Lossner U, and Paschke R. Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm Metab Res 35: 147-152, 2003.
7. Febbraio MA, Ott P, Nielsen HB, Steensberg A, Keller C, Krustrup P, Secher NH, and Pedersen BK. Exercise induces hepatosplanchnic release of heat shock protein 72 in humans. J Physiol 544: 957-962, 2002.
8. Fried SK, Bunkin DA, and Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847-850, 1998.
9. Hall G van, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, and Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005-3010, 2003.
10. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, and Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995.
11. Hotamisligil GS, Shargill NS, and Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993.
12. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, and Yano Y. Serum levels of tumor necrosis factor alpha increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83: 859-862, 1998.
13. Kern PA, Ranganathan S, Li C, Wood L, and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745-E751, 2001.
14. McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 52: 465-477, 1999.
15. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, and Kibata M. Relationship between serum tumor necrosis factor alpha and insulin resistance in obese men with type 2 diabetes mellitus. Diabetes Res Clin Pract 52: 119-123, 2001.
16. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, and Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82: 4196-4200, 1997.
17. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, and Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45: 805-812, 2002.
18. Pedersen BK, Steensberg A, and Schjerling P. Muscle-derived interleukin-6: possible biological effects. J Physiol 536: 329-337, 2001.
19. Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, Dela F, and Pedersen BK. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 124: 495-502, 2003.
20. Pradhan AD, Manson JE, Rifai N, Buring JE, and Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334, 2001.
21. Ridker PM, Rifai N, Stampfer MJ, and Hennekens CH. Plasma concentration of interleukin-6 and the risk of future mycocardial infarction among apparently healthy men. Circulation 101: 1767-1772, 2000.
22. Saghizadeh M, Ong JM, Garvey TW, Henry RR, and Kern PA. The expression of TNF-alpha by human muscle. J Clin Invest 97: 1111-1116, 1996.
23. Soop M, Duxbury H, Agwunobi AO, Gibson JM, Hopkins SJ, Childs C, Cooper RG, Maycock P, Little RA, and Carlson GL. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab 282: E1276-E1285, 2002.
24. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793, 1998.
25. Starkie RL, Arkinstall MJ, Koukoulas I, Hawley JA, and Febbraio MA. Carbohydrate ingestion attenuates the increase in plasma interleukin-6, but not skeletal muscle interleukin-6 mRNA, during exercise in humans. J Physiol 533: 585-591, 2001.
26. Starkie RL, Ostrowski SR, Jauffred S, Febbraio MA, and Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17: 884-886, 2003.
27. Steensberg A, Fischer C, Keller C, Møller K, and Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 285: E433-E437, 2003.
28. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, and Pedersen BK. IL-6 and TNF-α expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283: E1272-E1278, 2002.
29. Vicennati V, Vottero A, Friedman C, and Papanicolaou DA. Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord 26: 905-911, 2002.
30. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, and Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9: 414-417, 2001.
31. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, and Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79, 2002.
32. Yudkin JS, Kumari M, Humphries SE, and Mohammed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148: 209-214, 2000.